Welcome to our dedicated page for Adaptive Biotechnologies Corporation news (Ticker: ADPT), a resource for investors and traders seeking the latest updates and insights on Adaptive Biotechnologies Corporation stock.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) is a commercial-stage biotechnology company dedicated to leveraging the intricate biology of the adaptive immune system to innovate in the diagnosis and treatment of diseases. The company's proprietary immune medicine platform combines high-throughput sequencing with cutting-edge computational infrastructure to offer detailed analyses of T- and B-cell repertoires, critical elements in the body's immune response. Adaptive focuses on two primary business areas: Minimal Residual Disease (MRD) and Immune Medicine.
One of Adaptive's flagship products is clonoSEQ®, a highly sensitive and standardized test authorized by the FDA for detecting minimal residual disease (MRD) in patients with multiple myeloma (MM), B-cell acute lymphoblastic leukemia (B-ALL), and chronic lymphocytic leukemia (CLL). The clonoSEQ test is also available as a CLIA-validated laboratory developed test (LDT) for other lymphoid cancers, such as diffuse large B-cell lymphoma (DLBCL). The MRD status measured by clonoSEQ serves as a powerful predictor of patient outcomes, aiding in personalized treatment and monitoring strategies.
Adaptive Biotechnologies has formed strategic partnerships with leading biopharmaceutical companies. For instance, it collaborates with Genentech on T-cell receptor (TCR) based therapeutic products, providing a neoantigen-specific T-cell receptor identified using Adaptive's TCR discovery platform. The company also signed a multi-year collaboration with BeiGene to use clonoSEQ technology in developing novel therapies for lymphoid malignancies.
In terms of financial achievements, for the year ended December 31, 2023, Adaptive reported a total revenue of $170.3 million, with the MRD revenue contributing significantly to this growth. The company achieved substantial progress in clonoSEQ test volume and introduced strategic updates to maximize the value of its MRD and Immune Medicine businesses.
Adaptive Biotechnologies operates from biotech hubs in Seattle, Washington, and South San Francisco, California. Their team of world-class scientists and open, collaborative culture drive continuous innovation. The company's clinical diagnostics and pipeline developments aim to transform the clinical landscape, offering new hope for treating cancers, autoimmune disorders, and infectious diseases.
Recently, Adaptive Biotechnologies announced significant progress and strategic decisions to enhance its business operations. They integrated clonoSEQ into Epic’s specialty diagnostics suite, easing MRD monitoring accessibility for healthcare providers. The company continues to focus on driving operational efficiencies, as reflected by a decrease in operating expenses while maintaining sustainable growth.
Adaptive Biotechnologies remains committed to leveraging the adaptive immune system's potent capabilities to develop and commercialize immune-driven clinical products tailored to individual patient needs. With a robust cash position, Adaptive aims for profitability in its MRD business while making targeted investments in Immune Medicine.
Adaptive Biotechnologies (Nasdaq: ADPT) announced its upcoming presentation at IDWeek 2021, showcasing its immune medicine platform's capacity to differentiate between natural infections and vaccine responses related to SARS-CoV-2. New studies indicate that the T-cell response remains detectable nearly 12 months after positive PCR tests. The T-Detect™ COVID test, the first T-cell-based assay in the U.S., confirms prior infections through whole blood samples. The findings are significant for vaccine efficacy, diagnostics, and ongoing research into immune responses.
Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in the virtual Morgan Stanley Global Healthcare Conference on September 14, 2021, at 8:00 a.m. PT. The company will engage in a fireside chat, accessible via a live and archived webcast on their Investors webpage. Adaptive Biotechnologies focuses on leveraging the adaptive immune system to develop innovative clinical products for disease diagnosis and treatment. The company has three commercial products and a strong clinical pipeline addressing conditions like cancer and autoimmune diseases.
Adaptive Biotechnologies Corp. (Nasdaq: ADPT) and Curebase have partnered to enhance patient participation in clinical studies, focusing on Adaptive's T-Detect™ diagnostic test. The collaboration will initially target Lyme disease and COVID-19 patient data collection. With Curebase's decentralized trial model, studies can reach remote populations while preserving patient-provider relationships. The need for modernization in clinical trials is emphasized, particularly in increasing access for underrepresented patient groups.
Adaptive Biotechnologies has appointed Nitin Sood as the new chief commercial officer effective immediately. With over 15 years in the diagnostics and life sciences sectors, Sood's experience includes significant roles at Guardant Health and NuGEN. His appointment coincides with Adaptive's strategy for commercial growth and upcoming product launches, including immunoSEQ, clonoSEQ, and T-Detect. CEO Chad Robins emphasized Sood's proven ability to build and scale commercial organizations as vital for the company’s expansion plans.
Adaptive Biotechnologies reported financial results for Q2 2021, showcasing 83% revenue growth year-over-year, reaching $38.5 million. Sequencing revenue grew by 132% to $18.6 million, while development revenue rose 53% to $20 million. Despite this growth, the company faced an operating loss of $49.3 million, worsening from $33.5 million in Q2 2020. The company has $689.5 million in cash and expects to generate $148 million to $155 million in revenue for the full year 2021, indicating 54% growth at the midpoint.
Adaptive Biotechnologies (Nasdaq: ADPT) will release its financial results for Q2 2021 after market close on August 4, 2021. A conference call with management will follow at 1:30 PM PT/4:30 PM ET, accessible via their website. The company focuses on decoding the adaptive immune system to develop diagnostics and treatments for diseases, including cancer and autoimmune conditions. They boast three commercial products and a comprehensive clinical pipeline aimed at personalized immune-driven therapies.
Adaptive Biotechnologies announces the use of its immunoSEQ T-MAP COVID technology in a Nature study demonstrating T-cell immune response to the Johnson & Johnson COVID-19 vaccine against variants like B.1.351. The findings suggest preserved T-cell responses, even as neutralizing antibodies wane, indicating T-cells may offer essential protection from variants. The research underscores the importance of measuring T-cell responses in vaccine trials, especially against emerging strains.
Adaptive Biotechnologies (Nasdaq: ADPT) is set to present over 20 abstracts focusing on its clonoSEQ® Assay for assessing minimal residual disease (MRD) in blood cancers at the upcoming ASCO and EHA meetings. The clonoSEQ Assay is the first FDA-cleared test for MRD in chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and B-cell acute lymphoblastic leukemia (B-ALL). The results emphasize its clinical relevance, particularly in monitoring treatment response and potential relapses.
Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in two upcoming investor conferences. The company will engage in a fireside chat at the William Blair 41st Annual Growth Stock Conference on June 1st at 6:40 a.m. PT and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8th at 12:50 p.m. PT. Interested parties can access the live and archived webcasts via the company’s website. Adaptive Biotechnologies focuses on translating the adaptive immune system's genetics into clinical products for disease diagnosis and treatment.
Adaptive Biotechnologies (ADPT) reported strong financial results for Q1 2021, with revenue of $38.4 million, marking an 84% year-over-year increase. The growth was driven by a 60% increase in sequencing revenue and a 103% increase in development revenue. However, operating expenses rose to $79.7 million, leading to a net loss of $40.6 million, compared to a loss of $31.4 million in Q1 2020. The company anticipates full-year 2021 revenue between $145 million and $155 million, indicating 52% growth at the midpoint.
FAQ
What is the current stock price of Adaptive Biotechnologies Corporation (ADPT)?
What is the market cap of Adaptive Biotechnologies Corporation (ADPT)?
What is Adaptive Biotechnologies Corporation known for?
What is clonoSEQ?
Who are some of Adaptive Biotechnologies' key partners?
What were Adaptive Biotechnologies' financial highlights for 2023?
How does Adaptive Biotechnologies contribute to personalized medicine?
What recent strategic decisions has Adaptive Biotechnologies made?
Where are Adaptive Biotechnologies' main operations located?
What is the company culture at Adaptive Biotechnologies?
What are some key clinical applications of clonoSEQ?
What are Adaptive Biotechnologies' future goals?
